throbber
PAUL A. LASKAR, PH.D.
`
`Page 1
` IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
`APOTEX, INC.,
` Petitioner,
` Inter Partes Review No.:
`v. IPR2019-00400
`UCB BIOPHARMA SPRL,
` Patent Owner.
`~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
`
` VIDEO DEPOSITION OF
` PAUL A. LASKAR, Ph.D.
` October 2, 2019
` 9:31 a.m.
`
`Reported by: Audra M. Smith, RPR, FCRR
`Video by: David Cooper
`
`1
`2
`3
`4
`5
`
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 2
`
` APPEARANCES OF COUNSEL
`ON BEHALF OF THE PETITIONER:
`KATTEN MUCHIN ROSENMAN, LLP
`BY: JITENDRA MALIK, ESQUIRE
`BY: ALISSA M. PACCHIOLI, ESQUIRE
`550 S. Tryon Street, Suite 2900
`Charlotte, NC 28202
`Phone: 704.444.2000
`jitty.malik@kattenlaw.com
`alissa.pacchioli@kattenlaw.com
`ON BEHALF OF THE PATENT OWNER:
`FENWICK & WEST LLP
`BY: ERICA R. SUTTER, ESQUIRE
`650 California Street 26th Floor
`San Francisco, CA 94108-2615
`esutter@fenwick.com
`BY: ROBERT E. COUNIHAN, ESQUIRE
`1211 Avenue of the Americas, 32nd Floor
`New York, NY 10036
`Phone: 212.921.2001
`rcounihan@fenwick.com
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`1
`
`23
`
`4
`5
`6
`7
`
`89
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 3
`
` I N D E X
` *****
`PAUL A. LASKAR, Ph.D. PAGE
` Examination by Ms. Sutter 7
` Examination by Mr. Malik 148
` Examination by Ms. Sutter 155
` E X H I B I T S
`LASKAR EXHIBIT NUMBER DESCRIPTION PAGE
`Exhibit 1 Petition 10
`Exhibit 2 U.S. Patent Number 8,633,194 10
`Exhibit 3 Laskar CV 11
`Exhibit 4 United States Patent Number 5,698,558 12
`Exhibit 5 WO '094 Patent 12
`Exhibit 6 Handbook of Pharmaceutical
` Excipients, Third Edition 13
`Exhibit 7 European Patent Application
` Publication 0605203A2 13
`Exhibit 8 Opening Expert Report of Dr.
` Paul A. Laskar, Ph.D. in
` Case Number 18-CV-60846 in the
` United States District Court
` for the Southern District of
` Florida 18
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 4
`
` E X H I B I T S
`LASKAR EXHIBIT NUMBER DESCRIPTION PAGE
`Exhibit 9 Article, evaluation of the health
` aspects of methylparaben or review
` of the published literature
` by M.G. Soni, et al. 63
`Exhibit 10 Institution decision 74
`Exhibit 11 U.S. Patent 4,275,076 97
`Exhibit 12 Article, The treatment of atopic
` dermatitis with licorice gel 99
`Exhibit 13 Article, Topical disposition of two
` strengths of a I-125-rhEGF jelly in
` rat skin wounds 100
`Exhibit 14 U.S. Patent Number 5,643,584 101
`
`APOTEX EXHIBIT NUMBER DESCRIPTION PAGE
`Exhibit 1025 Case, Celanese v. Daicel 153
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 5
`
` P R O C E E D I N G S
` * * * * *
` THE VIDEOGRAPHER: We're going on the
` record at 9:31:55 a.m on October 2, 2019.
` Please note that the microphones are sensitive
` and may pick up whispering and other
` conversations. Please turn off all cell
` phones or put them away from the microphones
` as they can interfere with the deposition
` audio. Recording will continue until all
` parties agree to go off the record.
` This is Media Unit Number 1 in the video
` recorded deposition of Paul Laskar, Ph.D.
` Taken by counsel for the patent owner in the
` matter of Apotex, Inc. v. UCB BioPharma SPRL,
` Review Number IPR201900400, in the United
` States Patent and Trademark Office before the
` Patent Trial and Appeal Board. This
` deposition is being held at Katten Muchin
` Rosenman, LLP in the Conference Room F located
` at 5500 [sic] South Tryon Street, Suite 2905,
` Charlotte, North Carolina 28202. My name is
` David Cooper from Veritext. I'm the certified
` legal videographer. I'm not authorized to
` administer an oath. I'm not related to any
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 6
` parties in this action, nor am I financially
` interested in the outcome.
` Counsel and all present in the room will
` state their appearances and affiliation for
` the record. If there are any objections to
` the proceedings, please state them at the time
` of your appearance beginning with the noticing
` attorney.
` MS. SUTTER: Erica Sutter from Fenwick &
` West for the patent owner, UCB Biopharma SPRL.
` With me is my colleague Robert Counihan.
` MR. MALIK: Jitendra Malik from the law
` firm Katten, for Apotex. With me is
` Alissa Pacchioli.
` THE VIDEOGRAPHER: The court reporter,
` Audra Smith from Veritext will now swear in
` the witness.
` (The witness was sworn.)
` MR. MALIK: Just before we begin,
` pursuant to discussion with counsel regarding
` objections other than hearsay, relevance and
` foundation, when I say "form," all other
` objections are preserved. As far as document
` objections during the deposition, pursuant to
` 4264A, the parties agree to a five-day, five
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 7
` business day cure period for any supplemental
` evidence to an objection made to the -- to a
` document, but that that does not include
` bringing the witness back. And that agreement
` will be in place for all depositions going
` forward.
` Counsel, if I said that incorrectly,
` please go ahead and make any corrections.
` MS. SUTTER: I think we're good.
` * * * * *
` PAUL A. LASKAR,
`having been first duly sworn, was examined and testified
`before me as follows:
` EXAMINATION
`BY MS. SUTTER:
` Q. Good morning, Dr. Laskar, please state
` and spell your name for the record.
` A. P-A-U-L L-A-S-K-A-R.
` Q. Thank you. Can you please provide your
` business address?
` A. My business address is 603 Montecito
` Boulevard, Napa, California 94559.
` Q. And do you understand you're here today
` for a deposition?
` A. I do.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 8
` Q. Have you ever had your deposition taken
` before?
` A. Yes, I have.
` Q. How many times?
` A. I don't recall exactly. Between United
` States and Canada, their equivalent of a
` deposition, perhaps eight or ten times.
` Q. And have you ever been deposed for a
` proceeding before the United States Patent Trial
` Appeal Board?
` A. I have.
` Q. When was the last time you were deposed?
` A. Good question. I don't recall. Couple
` years ago, I believe.
` Q. So I'm just going to go over some ground
` rules to make sure that everyone is on the same
` page. You're probably familiar with these,
` though. We can't talk over each other. Please
` give audible responses. Court reporter can't take
` down when you're nodding your head or shaking your
` head. Do you understand?
` A. I do.
` Q. I'm going to ask you questions and you're
` to answer them to the best of your ability. Your
` counsel may object, but unless you're specifically
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 9
` instructed not to answer the question, you must
` still answer my question. Do you understand?
` A. Yes, I do.
` Q. And if you need me to repeat something,
` just let me know. Otherwise, if I don't hear from
` you, I'm going to assume that you understood the
` question. Is that fair?
` A. Yes, it is.
` Q. I'll try to take a break every hour or
` so. If you need a break earlier than that, you
` can let me know. Just -- I ask that you answer
` the last question; don't leave a question pending.
` Can we agree on that?
` A. We can.
` Q. Okay. Is there any reason you cannot
` testify truthfully today?
` A. No.
` Q. And you do understand you're under oath?
` A. I do understand that.
` Q. You submitted a declaration in this
` proceeding, correct?
` A. That's correct.
` (Exhibit Number 1 was marked.)
`BY MS. SUTTER:
` Q. I've had the court reporter mark Laskar
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 10
` Exhibit 1. It's placed in front of you. Is this
` your declaration in the petition?
` A. Yes, it is.
` Q. And your declaration relates to U.S.
` Patent Number 8,633,194; is that correct?
` A. Yes, that's correct.
` Q. You'll understand if I refer to that as
` the '194 patent?
` A. I will understand that, yes.
` (Exhibit Number 2 was marked.)
`BY MS. SUTTER:
` Q. I had the court reporter mark Laskar
` Exhibit 2, the '194 patent, and placed that in
` front of you. Does that look to be the patent
` that you referred to in your declaration?
` A. Yes, it does.
` Q. And you understand that the priority date
` for the '194 patent is July 14, 2004; is that
` correct?
` A. I do understand that.
` MR. MALIK: Object to form.
`BY MS. SUTTER:
` Q. You submitted a CV in this petition as
` well, correct?
` A. Yes, I did.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 11
`
` (Exhibit Number 3 was marked.)
`BY MS. SUTTER:
` Q. I had the court reporter mark Laskar
` Exhibit 3. It's Exhibit 1003 in the petition.
` Does that look to be your CV?
` A. Yes, it does.
` Q. Does anything need to be updated?
` A. Not substantially. Just under "Other,"
` I'm now a member of the Napa County Antismoking
` Coalition.
` Q. And your declaration states it's your
` opinion that Claims 1 through 11 of the '194
` patent are invalid as obvious; is that correct?
` A. Yes, it is.
` Q. And you proposed two grounds of
` obviousness, correct?
` A. Yes.
` Q. The first one relies on publication
` WO2004/050094. Is that correct?
` A. The patent that I refer to is the '094
` patent.
` Q. Correct. And you'll understand me then
` if I use the same terminology, '094?
` A. I will understand.
` Q. And that first ground also relies on what
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 12
` you referred to as the Handbook; it's the Handbook
` of Pharmaceutical Excipients, Third Edition, by
` Arthur Kibbe; is that correct?
` A. Yes, that's correct.
` Q. Your second ground of obviousness relies
` on three references, correct?
` A. Yes.
` Q. And that is European Patent Application
` Publication 0605203A2, or what you refer to as EP
` '203, correct?
` A. Correct.
` Q. The second one is United States Patent
` Number 5,698,558, or what you refer to as U.S.
` '558; is that correct?
` A. That's correct.
` Q. And the third reference is also the
` Handbook, correct?
` A. That's correct.
` (Exhibit Number 4 was marked.)
`BY MS. SUTTER:
` Q. Let's go ahead and mark those. So I've
` had the court reporter mark as Laskar Exhibit 4,
` the '558 patent. I had the court reporter mark as
` Exhibit 5 WO '094.
` (Exhibit Number 5 was marked.)
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 13
`
` (Exhibit Number 6 was marked.)
` (Exhibit Number 7 was marked.)
`BY MS. SUTTER:
` Q. I had the court reporter mark Laskar
` Exhibit 6 as the Handbook.
` Last one, Laskar Exhibit 7, is EP '203.
` So we can start with U.S. '558. Am I
` correct that you rely on U.S. '558 to argue that a
` person of ordinary skill would use levocetirizine
` instead of cetirizine in a pharmaceutical
` formulation?
` A. It is presumed that they would.
` Q. And you don't cite to any specific
` example in U.S. '558, correct?
` Strike that. You weren't referring --
` there's no specific formulation in U.S. '558 that
` you're referring to?
` A. No.
` Q. Go to WO '094. And you rely on WO '094
` for its statement regarding a pharmaceutical
` formulation that is a syrup; is that correct?
` A. Yes. As I indicate in my report, for
` example paragraph 61, I refer to a syrup
` composition.
` Q. And that is the syrup composition that's
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 14
` towards the bottom of page 4 of WO '094, right?
` A. Yes. At approximately line 33.
` Q. One of the reasons that you rely on the
` Handbook is for the statement that is in here
` twice. We can just use the first one on page 340.
` It says: Methylparaben together with
` propylparaben has been used for the preservation
` of various parenteral pharmaceutical formulations.
` Correct?
` A. Can you point me to where you're reading?
` Q. Yeah. It's on page 340, underneath that
` picture in top right corner?
` A. Right, yes.
` Q. I think it's also -- also in the
` propylparaben section as well. That one is in --
` it's in the first column on page 450, last
` paragraph.
` A. Yes. I see that, yes.
` Q. That's also a parenteral formulation,
` correct?
` A. I'm sorry?
` Q. It's also a parenteral formulation?
` A. It refers to parenteral formulations,
` yes.
` Q. In EP '203, you specifically point to
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 15
` Example 5. It's on page 11 of EP '203. And
` that's -- well, strike that.
` You rely specifically on Example 5 of EP
` '203 in your declaration, correct?
` A. Yes. As indicated in my paragraph 63,
` for example.
` Q. And Example 5 is an ophthalmic
` composition, correct?
` A. It is an ophthalmic formulation.
` Q. How did you identify these four
` references?
` A. They're -- they're pieces of prior art
` that I identified.
` Q. Did you identify them or did your counsel
` identify them?
` A. I identified them.
` Q. How did you find them?
` A. I'm very familiar with the Handbook of
` Pharmaceutical Excipients. I've used it routinely
` in my work since the first edition, and up till
` today. And in familiarizing myself with prior art
` through various search mechanisms, I identified
` some of these pieces of prior art.
` Q. Can you explain what you mean by
` different search mechanisms?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 16
`
` A. Internet search.
` Q. And so when you said that you identified
` the references through internet searches, was that
` relating to U.S. '558, WO '049, and EP '203?
` A. Yes.
` Q. And the Handbook is one that you knew
` before?
` A. The Handbook I was familiar with, totally
` independently and --
` Q. And these four are the only references
` you rely on as the base for your grounds of
` obviousness, correct?
` MR. MALIK: Object to form.
` A. It is, as I indicated in my report for my
` analysis of obviousness, under Ground 1, it is
` '094 and the Handbook. And for Ground 2, the '203
` and '558 and the Handbook. So as indicated in my
` report, those are the references I relied on.
`BY MS. SUTTER:
` Q. So the answer is yes?
` A. Yes.
` Q. You submitted your declaration in
` connection with Apotex's petition for inter partes
` review, correct?
` A. I'm sorry?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 17
` Q. You submitted your declaration in this
` proceeding in connection with Apotex's, Inc.'s
` petition for inter partes review; is that correct?
` A. Yes.
` Q. And you'll understand if I refer to
` Apotex, Inc. as just Apotex or petitioner?
` A. Yes.
` Q. And if I refer to inter partes review as
` just "the petition"?
` A. You may have to remind me.
` Q. Okay. Fair enough. Did you review
` Apotex's petition before you submitted your
` declaration?
` A. No.
` Q. Have you seen Apotex's petition?
` A. No.
` Q. What have you done in preparation for
` today's deposition?
` A. I refamiliarized myself with my
` declaration, my report; and the references,
` attachments, exhibits, your term -- I guess is the
` term used, the exhibits that I reference or
` mention in my report. I -- and then I have met
` with counsel over the last two days to review the
` information.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 18
` Q. You also submitted an expert report in a
` district court litigation regarding the '194
` patent, correct?
` A. I don't know. I don't know. Don't
` recall.
` MR. MALIK: I object to the document.
` Move to strike on the basis of relevance.
` (Exhibit Number 8 was marked.)
`BY MS. SUTTER:
` Q. I've had the court reporter mark Laskar
` Exhibit 8. It's the Opening Expert Report of
` Dr. Paul A. Laskar, Ph.D. in Case Number
` 18-CV-60846 in the United States District Court
` for the Southern District of Florida.
` Does this refresh your recollection as to
` whether you submitted an expert report in the
` district court litigation?
` A. Yes, it does.
` Q. Is your declaration in this proceeding
` based off of your district court report?
` MR. MALIK: Object to form.
` A. I would have to review this report in
` order to make a definitive statement. But the --
` there are -- the '049, the '203 the Handbook, and
` '558 as bases for my opinions, so I would believe
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 19
` that there is a -- there is a similarity between
` the two.
`BY MS. SUTTER:
` Q. Did you write your declaration?
` A. Yes.
` Q. Did you write your -- do you recall if
` you wrote your opening report?
` A. I would have. That is my standard
` procedure.
` MR. MALIK: Objection, scope.
`BY MS. SUTTER:
` Q. How many hours did you spend drafting
` these reports?
` A. I have no recollection of this time. I
` would have to review my calendar.
` Q. Do you have an approximation?
` A. No. It would be taken from thin air.
` Q. Did you talk to anyone else in forming
` your opinions?
` A. Anyone else besides whom?
` Q. In the industry. Anyone besides counsel.
` A. No.
` Q. And did you identify other pharmaceutical
` formulations to help form your opinions?
` MR. MALIK: Objection, form.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 20
` A. I'm not sure I understand the question.
`BY MS. SUTTER:
` Q. When writing your declaration, did you
` look at any other types of pharmaceutical
` formulations and consider those?
` A. That's still vague. There are several
` formulations mentioned in the prior art so,
` obviously, that prior art was part of my
` consideration. I'm not sure what else -- what
` other -- what else you're asking.
` Q. What I'm getting at is if you went and
` found pharmaceutical formulations and identified
` their compositions.
` MR. MALIK: Objection, form.
` A. Formulations of what?
`BY MS. SUTTER:
` Q. Pharmaceutical formulations other than
` what you have in the patent.
` MR. MALIK: Objection, form.
` A. Of what drug?
`BY MS. SUTTER:
` Q. Any -- any pharmaceutical formulation.
` MR. MALIK: Objection, form.
` A. I did not do any specific research of
` other formulations or drugs. As a -- someone
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 21
` who's an expert in pharmaceutical formulations,
` I'm certainly aware of a myriad of drugs and
` formulations. That's just part of my toolkit.
`BY MS. SUTTER:
` Q. And then out of your myriad of
` formulations, the key ones that you focused in on
` are the four that we've been discussing: WO '094,
` U.S. '558, the Handbook, and EP '203?
` A. And the other supporting documents that
` are referenced in my declaration.
` Q. Okay. Are you aware of what happened in
` district court litigation? Strike that.
` Prior to me showing you your report from
` the district court litigation, were you aware of
` the district court litigation regarding the '194
` patent?
` A. I was at the time. It has obviously
` skipped my mind.
` Q. Do you know if any other expert reports
` have been submitted in that litigation?
` MR. MALIK: Answer "yes" or "no." Don't
` get into communication with counsel.
` A. Not that I'm aware of.
`BY MS. SUTTER:
` Q. Have you been shown any other expert
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 22
`
` reports regarding the '194 patent?
` A. No.
` Q. And I think you've said a couple of times
` that you have experience formulating
` pharmaceuticals; is that correct?
` A. Yes.
` Q. Have any made it to market?
` A. Yes.
` Q. How many?
` A. Perhaps a dozen, I guess, something of
` that order.
` Q. What types of products are those?
` A. Ophthalmic products, dermatologicals. It
` hasn't been approved, but a liquid-filled capsule
` is at NDA stage, at NDA preparation stage, and
` then an injectable nebulize -- solution for
` nebulization that is an inhalation solution. It
` was a post-approval supplement for an oral syrup
` and an instant-release tablet. Those are the ones
` I can recall at this time.
` Q. And would you have used the Handbook in
` developing any of those?
` A. Yes. Once it became available. My
` career in the pharma industry predates the first
` edition of the Handbook. Sorry.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 23
` Q. Fair enough. How did you -- can you give
` an example of how you used the Handbook?
` A. It depends. Obviously depends on the
` nature of the dosage form, but it's to be due --
` to familiarize myself or refamiliarize myself with
` the attributes of the monographs that are
` described in the Handbook. And that -- you know,
` some of that familiarization, refamiliarization,
` is to identify any concerns there might be and
` what might be reasonable operating ranges of -- in
` terms of the quantity of the excipients that are
` reflected here. Those would be some of the uses I
` would make -- would make use of with the handbook.
` Q. When was the last time you were involved
` in developing a liquid pharmaceutical formulation?
` A. The present.
` Q. And what aspect of the formulation are
` you involved in?
` A. The -- identifying the -- what the
` product profile is, that is what the objective is
` for the formulation; and then identifying an
` appropriate composition, that is the excipients
` that are present and their -- and their target
` levels; developing acceptance criteria, i.e.
` specifications for those formulations; aiding or
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 24
` editing, reviewing the analytical methods that
` have been developed to determine whether the
` acceptance criteria have been met or not;
` identifying contract laboratories for testing;
` contract manufacturers for manufacturing;
` developing manufacturing procedures for the
` formulation at smaller and moving to larger scale;
` putting together regulatory documents that are
` relevant, the CMC, that is Chemistry Manufacturing
` and Control sections of regulatory filings at the
` IND level and the NDA level; interacting with
` regulatory agencies such as the FDA; beginning
` prior to filing the IND through its NDA review and
` responding to questions from the FDA. And I
` basically summarized much more briefly in my CV
` than what I just articulated.
` Q. So you mentioned identifying an
` appropriate composition based on the excipients
` that are present and identifying what the product
` profile is. What -- how would you go about
` identifying the appropriate excipients in
` composition?
` A. So that is based on what the product
` profile is, what it's intended to -- what it's
` going to look like at the end of the day when its
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 25
` NDA is approved, hopefully; what excipients would
` augment the attributes of the formulation, for
` example, in a tablet composition, to identify what
` would enhance its bioavailability and/or
` stability. In the case of other dosage forms,
` there would be some other attributes. Choose -- I
` would choose excipients that are known -- either
` known to be compatible or would have a reasonable
` likelihood of being compatible with the active
` drug or drugs that are in the composition. Those
` are some of the things that -- some of the
` decisions that I would need to make. When I say
` "I would need to make," I would need to discuss,
` and as a project team, would make decisions about.
` Q. Would you consider the route of
` administration?
` A. Absolutely.
` Q. And solubility of the components?
` A. Yes.
` Q. Would you consider things that a patient
` may be more interested in, such as color of the
` product?
` A. I'm sorry?
` Q. Would you consider characteristics that a
` patient may be more interested in, such as the
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 26
`
` color of the product?
` A. Yes.
` Q. Or the taste of the product?
` A. Absolutely.
` Q. And effective amount of the drug?
` A. That's one of the first items on the
` product profile is what is the anticipated
` clinical dose or, you know, amount to be
` administered to the patient.
` Q. Have you faced any challenges when
` developing your pharmaceutical formulations?
` A. Yes.
` Q. What are some of those challenges?
` A. Incompatibility of the drug with an
` excipient. In the case of topically administered
` products, the comfort. As you identified, the
` color or its absence, and then of course just the
` stability of the drug itself under environmental
` conditions. Those are some.
` Q. Are those considerations that you'd have
` to take into account with a liquid pharmaceutical
` product as well?
` A. Yes. I was -- and my mention of this was
` quite general across the array of dosage forms
` that I've been involved in over the past decades.
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 27
` Q. And so you mentioned that the tech
` preparation would have to be taken into
` consideration, if I recall correctly. What are
` some of those different considerations that you
` might have to consider, for example, with a liquid
` pharmaceutical formulation?
` A. Are you referring to a specific type of
` liquid formulation?
` Q. I was referring to generally unless
` you -- there are specific -- let's start
` generally.
` A. One is the route of administration of
` that liquid. There are considerations to be made
` depending on the route.
` Q. Can you explain that a little bit more?
` A. The considerations that I would need to
` take into account for an ophthalmic product, for
` example, are different than I would have to take
` into account for a liquid that is topically
` applied to the skin or inhaled or injected or
` administered orally.
` Q. So can you give me some examples of what
` you would consider in an oral liquid
` pharmaceutical in comparison to a liquid topical
` formulation?
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`212-279-9424
`
`Veritext Legal Solutions
`www.veritext.com
`
`212-490-3430
`
`UCB Biopharma SPRL (IPR2019-00400)
`Exhibit 2010
`
`

`

`PAUL A. LASKAR, PH.D.
`
`Page 28
` A. Liquid oral, as you've alluded to, has to
` have an acceptable taste profile in order that
` there be patient acceptance. The color is part of
` the aesthetics that would come into play for both
` oral and topical. Other aesthetics would be
` smell -- would be smell, both for oral

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket